Synthesis and biological evaluation of a series of 2-(((5-akly/aryl-1H-pyrazol-3-yl)methyl)thio)-5-alkyl-6-(cyclohexylmethyl)-pyrimi din-4(3H)-ones as potential HIV-1 inhibitors.
Abstract: M184V (62.04%), K103N (41.90%) and I54L (3.83%) were the most common observed mutations, respectively, in NRTI-, NNRTI- and PI-associated drug resistance.
Result: The most common primary NRTI mutations detected included M184V (62.04%), K65R (20.24%), K70R (15.01%), T215D/S (9.41%), Y115F (7.22%) and M41L (6.35%).
Table: M184V/I
Discussion: Although M184V/I causes high-level in vitro resistance to 3TC, PMID: 32205723
2020
AIDS (London, England)
Introduction: Moreover, an OLA-Simple kit that detects the NRTI mutation M184V and NNRTI mutations K103N, Y181C, and G190A was clinically validated across multiple HIV-1 subtypes, showing 99.6% sensitivity and 98.2% specificity compared to Sanger sequencing.
Method: A database containing HIVDR profiles from 2412 individuals initiating first-line ART in Mexico City genotyped by MiSeq was used to select 60 plasma specimens enriched for mutations K65R, K103N/S, Y181C, M184V, and G190A.
Method: OLA-Simple probes designed to detect K65R, PMID: 32264923
2020
BMC infectious diseases
Abstract: A plasma RNA genotype resistance test revealed wild-type virus in the integrase region and protease region (PR), but extensive resistance in the reverse transcriptase (RT) region (M41L, E44D, D67N, K70R, M184V, L210W and T215Y).
Conclusion: A genotype resistance test (GRT) in June 2002 (Trugene HIV-1 Genotyping Assay, Siemens Healthcare Diagnostics GmbH, Eschborn, Germany) showed extensive resistance in the RT region (M41L, E44D, D67
Drug Resistance Mutations Against Protease, Reverse Transcriptase and Integrase Inhibitors in People Living With HIV-1 Receiving Boosted Protease Inhibitors in South Africa.
Conclusion: Given the negative effect of M184V mutations on viral fitness, it is more plausible to the recycling of 3TC/FTC in second-line cART maintains the presence of M184V.
Conclusion: The majority of them had M184V mutations that could have been carried over from the first-line cART.
Result: M184V/I was also found in two (4%) patients receiving TDF plus 3TC, compared with those receiving FTC plus TDF (n = 1; 2%).
Result: M184V/I was detected in 52 (54%) patients suspected of failing cART.
Result: We observed M184V/I as the most prevalent NRTI mutation.
Table: M184V/I
Table: M184V
Discussion: In
HIV-1 Drug Resistance, Distribution of Subtypes, and Drug Resistance-Associated Mutations in Virologic Failure Individuals in Chengdu, Southwest China, 2014-2016.
Abstract: The leading DRMs observed in the study were M184I/V (59.59%) against NRTIs and K103N (37.55%) against NNRTIs.
Result: The most commonly observed mutations with NRTIs were M184I/V (59.59%, 146/245), K65R (28.16%, 69/245), D67N/G (19.18%, 47/245), K70E/K/R (17.14%, 42/245), Y115F (15.10%, 37/245), L74I/V (11.02%, 27/245), and T215I/Y (8.16%, 20/245).
Discussion: In our study, M184I/V (59.59%) was the most prevalent mutation associated with NRT
Characteristics of drug resistance in HIV-1 CRF55_01B from ART-experienced patients in Guangdong, China.
PMID: 32300784
2020
The Journal of antimicrobial chemotherapy
Abstract: Among DRMs, M184V (43.83%) was the most frequent NRTI DRM, followed by K65R (23.46%), and V179E (98.77%) was the most frequent NNRTI DRM, followed by K103N (47.53%) and Y181C (14.81%).
HIV-1 drug resistance mutations detection and HIV-1 subtype G report by using next-generation sequencing platform.
Abstract: NRTI and NNRTI associated dominant mutations were M184I/V and K103 N.High-level resistance to lamivudine (3 TC) and Emtricitabine (FTC) were detected in 34.3% of patients while 53.1% were resistant to Efavirenz (EFV) and Nevirapine (NVP).
HIV-1 Drug Resistance in ART-Naive Individuals in Myanmar.
Discussion: Another survey focusing on Burmese individuals staying in Dehong reported that M184V, K103N/KN, and T74S/ST were the major SDRMs associated with VF.
Discussion: Furthermore, we found that the major NNRTI-related SDRMs were K101P, K103N, V106A, E138A, Y181C, and Y188H, and the major NRTI-related SDRMs were L74V/I and M184V.
Discussion: Some SDRMs, including NRTI-related mutations (M41L, D6
Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO).
Discussion: Additional support for this hypothesis comes from two retrospective cohort studies in which a historical plasma genotype detecting the M184V mutation was not predictive of virologic failure in participants switching to lamivudine- based dual therapies with either a protease inhibitor or an integrase inhibitor.
Discussion: Another study reported lower viral rebound in persons harboring the M184V who received lamivudine monotherapy compared to patients interrupting treatment.
Discussion: dual therapy with either boosted protease inhibitor or integrase inhibitor plus lamivudine in persons with past M184V demonstrated only a statistically higher risk of virological failure for those with a viral suppression equal or under three yea
HIV mutation literature information.
PMID: 
2020
Acta pharmaceutica Sinica. B
Browser Board
Co-occurred Entities
Filtrator
ViMRT